SEC Tracker
Get the app

KLA KLAC

KLA FY 2024: revenue $9.8B, down 7%; diluted EPS $0.00

Form
10-K
Filed
Period
Importance
Notable
Document
10-K

Key figures from this report

These are the numbers KLA reported for the year ended Jun 30, 2024, as tagged in the filing’s XBRL data, each against the year before. A plain-English reading of this report is not written yet.

  1. Revenue$9.8B−7% from $10.5B in FY 202310-K income statement, on EDGAR
  2. Net income$2.8B−18% from $3.4B in FY 202310-K income statement, on EDGAR
  3. Diluted EPS$0.00Flat against $0.00 in FY 2023. Split-adjusted, as the tables show it; the filing reported $20.2810-K income statement, on EDGAR
  4. Cash and cash equivalents$2.0B+3% from $1.9B in FY 202310-K balance sheet, on EDGAR
  5. Cash from operations$3.3B−10% from $3.7B in FY 202310-K cash flow statement, on EDGAR

Every year in the financial tables

View on EDGAR

Open in the app

Get an email when KLA files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 3827 and related industry codes: the same peer list as the financial tables.

  1. Thermo Fisher Scientific TMO public float $154.0B, Jun 27, 2025
  2. Danaher DHR public float $125.9B, Jun 30, 2025
  3. Trane Technologies TT public float $97.2B, Jun 30, 2025
  4. Roper Technologies ROP public float $60.8B, Jun 30, 2025
  5. Ametek AME public float $41.8B, Jun 30, 2025